TD Asset Management Inc Sells 56,771 Shares of Medtronic PLC $MDT

TD Asset Management Inc cut its position in Medtronic PLC (NYSE:MDT) by 4.8% in the third quarter, HoldingsChannel.com reports. The firm owned 1,117,213 shares of the medical technology company’s stock after selling 56,771 shares during the period. TD Asset Management Inc’s holdings in Medtronic were worth $106,403,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Delos Wealth Advisors LLC bought a new position in shares of Medtronic during the 2nd quarter worth approximately $27,000. Corundum Trust Company INC purchased a new position in Medtronic in the third quarter worth $27,000. Valley Wealth Managers Inc. acquired a new position in shares of Medtronic during the third quarter worth $29,000. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medtronic during the 3rd quarter valued at $33,000. Finally, Tripletail Wealth Management LLC acquired a new stake in shares of Medtronic in the 3rd quarter worth $34,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on MDT. Royal Bank Of Canada upped their target price on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. JPMorgan Chase & Co. cut their price objective on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Daiwa Securities Group increased their price objective on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Wells Fargo & Company began coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 target price on the stock. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and an average price target of $110.84.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Diabetes unit, MiniMed, has priced an IPO targeting up to $784M (28M shares at $25–$28). The move advances the planned spin‑off and could unlock value for Medtronic shareholders by creating a focused, public diabetes company. Medtronic’s MiniMed prices IPO at up to $784M
• Positive Sentiment: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor commercially across EMEA — the first app to combine InPen smart‑pen data with Simplera sensor data. Europe rollout expands MiniMed’s addressable market and supports recurring revenue from diabetes consumables and services. Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor
• Positive Sentiment: Medtronic also reported FDA clearance for its Stealth AXiS spine surgical system (noted in coverage of its portfolio reshaping), which could boost its spine franchise and procedure‑related revenue over time. Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval
• Neutral Sentiment: MiniMed’s IPO roadshow is underway with an investor presentation and expected pricing timeline; investors will watch subscription demand and final pricing for signals about appetite for diabetes assets. MiniMed announces launch of IPO roadshow
• Neutral Sentiment: Reports cite a potential MiniMed valuation near $7.9B—valuation and the amount Medtronic retains (or sells) will determine the magnitude of balance‑sheet and EPS impact. Medtronic’s diabetes unit MiniMed eyes $7.9 billion valuation in US IPO
• Neutral Sentiment: Analyst commentary (e.g., “inflection trade” coverage) suggests investors see a potential turnaround if new product approvals and the portfolio split accelerate growth; this is sentiment‑driven and depends on execution. Why the Medtronic (MDT) ‘Inflection Trade’ is Back On
• Negative Sentiment: Spin‑off/IPO risk — separating MiniMed reduces Medtronic’s near‑term revenue base and could introduce one‑time costs, dilution or changes to reported EPS and margin metrics; some investors may discount MDT shares until the post‑split capital allocation is clear. Medtronic’s diabetes business MiniMed looks for $784m in US IPO
• Negative Sentiment: Industry competition and lobbying developments (e.g., new diabetes sector leadership) highlight competitive pressure in diabetes tech that could affect market share and pricing over time. AdvaMed names Jake Leach as chair of diabetes sector

Medtronic Price Performance

Shares of NYSE:MDT opened at $96.71 on Thursday. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The company has a market cap of $123.98 billion, a PE ratio of 26.94, a price-to-earnings-growth ratio of 2.43 and a beta of 0.71. The company’s 50 day moving average is $98.98 and its 200 day moving average is $96.83.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).